fda ruling tirzepatide Compounders lose battle over Eli Lilly weight loss drug and shortage list US judge sides with FDA's

Finally, the ongoing SURPASS-CVOT is like the boss battle: the mother of all GLP-1 agonist clinical trials

Adverse Reactions: Most common adverse reactions (incidence 5%) in adults or pediatric patients aged 12 and older are: nausea, diarrhea, vomiting, constipation, abdominal pain, dysesthesia, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and hair loss

Researchers think that the satiety effects of GLP-1s may be related to their actions on the brains dopamine reward system

Experience in bariatrics, particularly over 20 years, is invaluable

Blood samples for PK measurements were collected on day 28 (predose and at 0.5, 1, 2, 4, 6, 8, 12, and 16 h postdose) and day 29 (predose)